New twist to an old problem: COVID-19 and idiopathic pulmonary fibrosis.
Pratap UpadhyaRavindra Chari MGopal ChawlaRohit VadalaMadhusmita MohantyPublished in: Advances in respiratory medicine (2021)
Iidiopathic pulmonary fibrosis (IPF) diagnosis and treatment during this COVID-19 pandemic have been affected. COVID-19 has not only impacted the prognosis of these patients but also the approach to these patients. Pulmonary function tests (PFT) and lung biopsies are less encouraged now. Traditional antifibrotics used in IPF should be encouraged irrespective of patient lung function and in those with non-definite usual interstitial pneumonia in high resolution computed tomography.
Keyphrases
- idiopathic pulmonary fibrosis
- computed tomography
- lung function
- end stage renal disease
- high resolution
- coronavirus disease
- newly diagnosed
- ejection fraction
- sars cov
- chronic obstructive pulmonary disease
- magnetic resonance imaging
- pulmonary fibrosis
- cystic fibrosis
- mass spectrometry
- epithelial mesenchymal transition
- patient reported outcomes
- positron emission tomography
- respiratory syndrome coronavirus
- dual energy